Yükleniyor... / Loading...
A Study of MK-8033 in Patients With Advanced Solid Tumors (MK-8033-001)
Bu çalışma, standart tedavisi yeterli olmayan ileri solid (katı) tümörü olan hastalarda MK-8033 adlı ilacı inceliyor. 18 yaş üstü, organ işlevleri yeterli hastalar dahil edilmiştir. Faz 1 aşamasında yürütülmüş ve tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * Patient must be at least 18 years of age, with adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance of \<2 * Patient must be willing to undergo pre-study and post-dose tumor biopsy and have tumor accessible for biopsy (Waived during Parts A and C) Exclusion Criteria: * Patient is currently using bisphosphonate therapy or has received this therapy in past 6 months * Patient has had chemotherapy, radiotherapy, or biological therapy within 4 weeks of study participation * Patient has history of cardiac disease * Patient with a primary central nervous system tumor * Patient has a known psychiatric or substance abuse disorder * Patient is pregnant or breastfeeding, or expecting to conceive during the study * Patient is known to be Human Immunodeficiency Virus (HIV) positive and the HIV infection is not well controlled * Patient has received therapy with a Proton-Pump Inhibitor, Histamine2-Receptor antagonist or antacid within one week of study participation (Part B only)